Guangdong Zhongsheng Pharmaceutical (002317.SZ): RAY1225 injection weight loss Phase II clinical trial obtains top-line analysis data results.

Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that a type of innovative peptide drug, RAY1225 injection developed independently by its holding subsidiary Guangdong Zhongsheng Ruichuang Biological Technology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has obtained top-line analysis data from the Phase II clinical trial for overweight/obese patients. The preliminary results indicate that RAY1225 injection has shown positive efficacy and good safety in Chinese adult overweight/obese participants, with the trial results meeting expectations. The announcement also revealed that Phase II clinical studies for RAY1225 injection in overweight/obese patients and type 2 diabetes patients are ongoing. The Phase II clinical trial for overweight/obese patients (REBUILDING-1) recently completed the database cleaning and locking for Part A sub-study, obtaining top-line analysis results that met the primary endpoint. The drug showed significant improvement in weight loss rates and various cardiovascular and metabolic risk factors compared to the placebo.